Scantox Group announces it has acquired the nonclinical genomic safety business of TwinStrand Biosciences, Inc. through a technology transfer and license agreement. Under the agreement, Scantox gains rights to be the sole provider of DuplexSeq™ Mutagenesis Assays and related nonclinical genomics safety services globally. The transaction addresses growing demand for advanced mutagenesis assessment as development teams face increasing pressure to make earlier, higher-confidence decisions on mutagenic risk with regulator-ready evidence. Through the agreement, Scantox will provide high-precision sequencing-based mutagenesis testing to the market at global CRO scale across both service and product offerings.
Read the full article: Scantox Acquires DuplexSeq™ Nonclinical Genomics Safety Business from TwinStrand Biosciences //
Source: https://www.prnewswire.com/news-releases/scantox-acquires-duplexseq-nonclinical-genomics-safety-business-from-twinstrand-biosciences-302698141.html